CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31

CervoMed Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$2.31+0.07 (+3.12%)

Close on Oct 19, 2026

Market cap: $23.66M
P/E (TTM): –
Dividend yield: –

CervoMed Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Depreciation & Amortization	–	–	–	0	0.09	0.10	–	–	–	–	0.02	0.57	0.12	0.16	0.07	0.05
Stock-Based Compensation	1.45	1.41	0.41	0.33	0.90	0.74	0.52	1.22	1.24	1.39	0.59	1.61	2.23	–	–	–
Deferred Income Taxes	–	–	–	0	-0.44	-1.68	0.33	-0.44	-1.06	-0.36	0	-2.82	–	–	–	–
Change in Accounts Receivable	1.83	-1.34	-0.92	–	–	–	–	–	–	–	–	–	–	–	–	–
Change in Accounts Payable	-0.07	0.85	0.57	0.08	0.61	0.95	0.57	-0.28	-1.66	0.99	0.65	-3.80	1.60	0.41	-0.11	0.52
Operating Cash Flow	-23	-17	-7.45	-2.57	-15	-14	-9.86	-11	-12	-11	-5.19	-9.03	-1.18	-4.31	-12	-1.98
Capital Expenditures	–	–	–	–	–	–	–	–	-0.45	0.00	-0.04	-0.05	–	–	–	–
Acquisitions	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.36	-1.37
Sale of Property, Plant & Equipment	–	–	–	0	0.00	0	–	–	–	–	–	–	–	–	–	–
Purchase of Investments	-25	-48	0	-38	0	–	–	–	–	–	-0.25	–	–	–	–	–
Sale & Maturity of Investments	44	19	0	26	0	–	–	–	10	0	2.50	–	–	–	–	–
Investing Cash Flow	18	-29	0	-12	0.00	0	–	–	-0.45	8.50	2.46	-0.05	–	–	-0.99	-1.38
Stock Issued	–	46	0.81	0	31	11	–	11	–	–	–	32	0.43	0.14	3.99	2.31
Financing Cash Flow	4.59	46	11	0	33	18	16	9.87	20	1.83	2.39	31	1.13	4.52	13	3.37
Net Change in Cash	-0.76	1.21	3.70	-2.57	19	4.34	6.19	-0.91	7.34	-0.44	-0.34	22	-0.06	0.21	0.10	–
Free Cash Flow	–	–	–	–	–	–	–	–	-13	-11	-5.23	-9.08	–	–	–	–
Income Taxes Paid	–	–	–	–	–	–	–	–	–	–	–	–	0	0	–	–
Interest Paid	–	–	–	–	–	–	–	0.04	0.11	–	–	0.68	0	0	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -9407.0%
Net margin: -9160.9%
Return on equity, FY2025: -93.9%

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: 71.43
Price to book: 1.03
Dividend yield: –